Abstract
PURPOSE: The effect of pravastatin, an inhibitor ofras p21 isoprenylation, on the gross type of colon tumors induced by azoxymethane was investigated in Wistar rats. METHODS: Rats received ten weekly subcutaneous injections of 7.4 mg/kg body weight of azoxymethane and intraperitoneal injections of 10 or 20 mg/kg body weight of pravastatin every other day until the end of the experiment at Week 45. RESULTS: Administration of pravastatin at both dosages had no significant effect on the incidence of colon tumors but significantly increased the incidence of rats with adenomas only. In contrast to the elevated adenomas in control rats, flat adenomas were significantly more prevalent in rats given pravastatin. Pravastatin at both doses significantly decreased the labeling index, but not the apoptotic index, of elevated adenomas, whereas it significantly decreased the labeling index but increased the apoptotic index of flat adenomas. Administration of pravastatin at both dosages also significantly decreased the amounts of membrane-associatedras p21 in colon tumors. CONCLUSIONS: These findings suggest that theras oncogene may be closely related to the development of adenocarcinomas from adenomas and the development of elevated or polypoid tumors of the colon.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Levin B, Raijman I. Malignant tumors of the colon and rectum. In: Haubrich WS, Schaffner F, Berk JE, eds. Bockus gastroenterology, 5th ed. Philadelphia: WB Saunders, 1995:1744–72.
Vogelstein B, Fearon ER, Hamilton SR,et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525–32.
Iishi H, Tatsuta M, Tsutsui S,et al. Early depressed adenocarcinomas of the large intestine. Cancer 1992;69:2406–10.
Fujimori T, Satonaka K, Yamamura-Idei Y, Nagasako K, Maeda S. Non-involvement ofras mutations in flat colorectal adenomas and carcinomas. Int J Cancer 1994;57:51–5.
Minamoto T, Sawaguchi K, Mai M, Yamashita N, Sugimura T, Esumi H. Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. Cancer Res 1994;54:2841–4.
Egan SE, Weinberg RA. The pathway to signal achievement. Nature 1993;365:781–3.
McCormick F. How receptors turn RAS on. Nature 1993;363:15–6.
Sinensky M, Beck LA, Leonard S, Evans R. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 1990;265:19937–41.
Tatsuta M, Iishi H, Baba M,et al. Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br J Cancer 1998;77:581–7.
Vivona AA, Shpitz B, Medline A,et al. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 1993;14:1771–81.
Shivapurkar N, Tang Z, Ferreira A, Nasim S, Garett C, Alabaster O. Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in Fischer-344 rats on high-risk diet. Carcinogenesis 1994;15:775–8.
Singh J, Kulkarni N, Kelloff G, Reddy BS. Modulation of azoxymethane-induced mutational activation ofras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 1994;15:1317–23.
Rubio C, Shetye J. Flat adenoma-adenocarcinoma sequence in the colon of rats. Dis Colon Rectum 1994;37:1300–6.
Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982;218:474–5.
Morstyn G, Hsu S-M, Kinsella T, Gratzner H, Russo A, Mitchell JB. Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody. J Clin Invest 1983;72:1844–50.
Törmänen U, Eerola A-K, Rainio P,et al. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 1995;55:5595–602.
Takahashi-Fujii A, Ishino Y, Shimada A, Kato I. Practical application of fluorescence-based image analyzer for PCR single-stranded conformation polymorphism analysis used in detection of multiple point mutations. PCR Methods Appl 1993;2:323–7.
Ura H, Obata T, Nishino N, Tanno S, Okumura K, Namiki M. Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutantras gene. Jpn J Cancer Res 1994;85:633–8.
Miller RG Jr. Simultaneous statistical inference. New York: McGraw-Hill, 1966.
Morris TJ, Palm SL, Furcht LL, Buchwald H. Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth. Ann Surg Oncol 1995;2:266–74.
Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y. Modulation of the mevalonate pathway and cell growth by pravastatin andd-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 1994;69:1015–20.
Narisawa T, Fukaura Y, Terada K,et al. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994;15:2045–8.
Tsujitani S, Shirai H, Tatebe S,et al. Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma. Cancer 1996;77:1711–6.
Okuyama S, Yokota K, Yuki M. Cell proliferation and cell death (apoptosis) in epithelial tumors of the stomach—analysis of tumor tissues by the endoscopic mucosal resection. Jpn J Gastroenterol 1995;92:130–9.
Ura H, Ohara T, Takago Y. Farnesyl transferase inhibitors induces apoptosis in cultured pancreatic cell lines. J Jpn Soc Gastroenterol Carcinog 1997;9:67–8.
Author information
Authors and Affiliations
Additional information
Supported in part by a Grant-in-Aid for the Second-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare, Japan.
About this article
Cite this article
Iishi, H., Tatsuta, M., Baba, M. et al. ras p21 isoprenylation inhibition induces flat colon tumors in Wistar rats. Dis Colon Rectum 43, 70–75 (2000). https://doi.org/10.1007/BF02237247
Issue Date:
DOI: https://doi.org/10.1007/BF02237247